Literature DB >> 14604504

Diagnosis, epidemiology, and impact of tension-type headache.

Rigmor Jensen1.   

Abstract

Although tension-type headache is the most prevalent headache and affects 78% of the general population, the substantial societal and individual burden associated with this primary headache has been overlooked. In contrast to migraine headache, there has been limited focus on tension-type headache. Most patients with the chronic form of tension-type headache, which affects 3% of the population, are left virtually without any specific treatment. Chronic tension-type headache differs from the episodic form in frequency, lack of effect to most treatment strategies, more medication overuse, and more loss of quality of life. Daily or near daily headaches also constitute a major diagnostic and therapeutic problem and distinguishing chronic tension-type headache from migraine headache and from medication-induced headache is a substantial diagnostic challenge because management strategies are completely different. Considerable benefits for the society can be gained by specific strategies leading to reductions in the amount of sickness absence and impaired working abilities. The burden on the affected patients' and their families' quality of life also may be improved by a general acceptance of the disorder and by the development of a specific treatment strategy.

Entities:  

Mesh:

Year:  2003        PMID: 14604504     DOI: 10.1007/s11916-003-0061-x

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  39 in total

1.  Frequency of headache in the medical students of Santa Catarina's Federal University.

Authors:  M Z da Costa; C B Soares; L M Heinisch; R H Heinisch
Journal:  Headache       Date:  2000-10       Impact factor: 5.887

2.  Epidemiological aspects of headache in a workplace setting and the impact on the economic loss.

Authors:  P H M Pop; C M Gierveld; H A M Karis; H G M Tiedink
Journal:  Eur J Neurol       Date:  2002-03       Impact factor: 6.089

3.  Psychosocial correlates and impact of chronic tension-type headaches.

Authors:  K A Holroyd; M Stensland; G L Lipchik; K R Hill; F S O'Donnell; G Cordingley
Journal:  Headache       Date:  2000-01       Impact factor: 5.887

4.  Clinical features of withdrawal headache following overuse of triptans and other headache drugs.

Authors:  Z Katsarava; G Fritsche; M Muessig; H C Diener; V Limmroth
Journal:  Neurology       Date:  2001-11-13       Impact factor: 9.910

Review 5.  Central sensitization in tension-type headache--possible pathophysiological mechanisms.

Authors:  L Bendtsen
Journal:  Cephalalgia       Date:  2000-06       Impact factor: 6.292

6.  Lost workdays and decreased work effectiveness associated with headache in the workplace.

Authors:  B S Schwartz; W F Stewart; R B Lipton
Journal:  J Occup Environ Med       Date:  1997-04       Impact factor: 2.162

7.  Epidemiology of tension-type headache in Santiago, Chile: a prevalence study.

Authors:  P M Lavados; E Tenhamm
Journal:  Cephalalgia       Date:  1998-10       Impact factor: 6.292

8.  Migraine and tension-type headache in a general population: precipitating factors, female hormones, sleep pattern and relation to lifestyle.

Authors:  Birthe Krogh Rasmussen
Journal:  Pain       Date:  1993-04       Impact factor: 6.961

9.  Migraine and tension-type headache in a general population: psychosocial factors.

Authors:  B K Rasmussen
Journal:  Int J Epidemiol       Date:  1992-12       Impact factor: 7.196

10.  Lifetime prevalence and characteristics of recurrent primary headaches in a population-based sample of Swedish twins.

Authors:  Dan A Svensson; Karl Ekbom; Bo Larsson; Elisabet Waldenlind
Journal:  Headache       Date:  2002-09       Impact factor: 5.887

View more
  16 in total

1.  Chiropractors and collaborative care: An overview illustrated with a case report.

Authors:  John J Riva; Gloria D Muller; Adrian A Hornich; Silvano A Mior; Anita Gupta; Stephen J Burnie
Journal:  J Can Chiropr Assoc       Date:  2010-09

Review 2.  Chronic orofacial pain.

Authors:  Sowmya Ananthan; Rafael Benoliel
Journal:  J Neural Transm (Vienna)       Date:  2020-03-04       Impact factor: 3.575

3.  Has the prevalence of migraine and tension-type headache changed over a 12-year period? A Danish population survey.

Authors:  Ann Christine Lyngberg; Birthe K Rasmussen; Torben Jørgensen; Rigmor Jensen
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

Review 4.  Epidemiology of tension-type headache.

Authors:  Sara C Crystal; Matthew S Robbins
Journal:  Curr Pain Headache Rep       Date:  2010-12

5.  Myofascial trigger point-focused head and neck massage for recurrent tension-type headache: a randomized, placebo-controlled clinical trial.

Authors:  Albert F Moraska; Lea Stenerson; Nathan Butryn; Jason P Krutsch; Sarah J Schmiege; John D Mann
Journal:  Clin J Pain       Date:  2015-02       Impact factor: 3.442

Review 6.  Advances in the pharmacologic treatment of tension-type headache.

Authors:  Marcelo E Bigal; Alan M Rapoport; Richard Hargreaves
Journal:  Curr Pain Headache Rep       Date:  2008-12

7.  Changes in Clinical Parameters in Patients with Tension-type Headache Following Massage Therapy: A Pilot Study.

Authors:  Albert Moraska; Clint Chandler
Journal:  J Man Manip Ther       Date:  2008

8.  Changes in Psychological Parameters in Patients with Tension-type Headache Following Massage Therapy: A Pilot Study.

Authors:  Albert Moraska; Clint Chandler
Journal:  J Man Manip Ther       Date:  2009

9.  Migraine and the risk of dementia: a meta-analysis and systematic review.

Authors:  Wei Jiang; Guo-Hua Liang; Jia-Ai Li; Peng Yu; Ming Dong
Journal:  Aging Clin Exp Res       Date:  2022-01-31       Impact factor: 3.636

10.  Effectiveness of manual therapy compared to usual care by the general practitioner for chronic tension-type headache: design of a randomised clinical trial.

Authors:  René F Castien; Daniëlle A W M van der Windt; Joost Dekker; Bert Mutsaers; Anneke Grooten
Journal:  BMC Musculoskelet Disord       Date:  2009-02-12       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.